Australian public assessment report for Eculizumab

Neuromyelitis optic spectrum disorder (NMOSD) is regarded as an extremely rare inflammatory disorder of the central nervous system, with an age and sex adjusted incidence ranging between 0.07 to 0.73 per 100,000 person-years and prevalence ranging between 3.9 and 10 per 100,000 person-years worldwide. ................
................